Publications by authors named "F H Gwadry-Sridhar"
Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes among patients with resected stage IB-IIIA NSCLC tumors expressing PD-L1 using PALEOS (Pan-cAnadian Lung cancEr Observational Study) data (2016-2019). Key outcomes included PD-L1 expression rate and treatment patterns, recurrence, and median overall (mOS) and disease-free survival (mDFS) among PD-L1+ patients.
View Article and Find Full Text PDFRationale & Objective: The National Kidney Foundation (NKF) launched the first national US kidney disease patient registry, the NKF Patient Network, that is open to patients throughout the continuum of chronic kidney disease (CKD). The Network provides individualized education and will facilitate patient-centered research, clinical care, and health policy decisions. Here, we present the overall design and the results of a feasibility study that was conducted July through December 2020.
View Article and Find Full Text PDFArticle Synopsis
- The ADAURA trial highlighted the benefits of using adjuvant osimertinib for patients with early-stage, resected non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFRm).
- A study analyzing data from the PALEOS study found that 23% of patients tested for EGFRm were positive, with a mix of common and uncommon mutations, and noted that 46% of these patients received adjuvant therapy post-surgery.
- The findings showed significant recurrence rates, particularly in distant sites, with median overall survival varying based on the cancer stage and mutation type, indicating that patients with uncommon EGFRm had lower survival rates compared to those with
Background: Pathologic mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder, a genetic syndrome associated with severe epilepsy and cognitive, motor, visual, and autonomic disturbances. This disorder is a relatively common genetic cause of early-life epilepsy. A specific severity assessment is lacking, required to monitor the clinical course and needed to define the natural history and for clinical trial readiness.
View Article and Find Full Text PDFBackground: In North America, heart failure (HF) is the leading cause for hospital readmission. Supportive technology, such as computers and tablets, could potentially assist patients with self-care to manage their condition after hospital discharge; however, older individuals have difficulties in adopting technology to manage their condition.
Method: This study used a mixed methods design to identify barriers to technology use in HF self-care.